(Winter Haven, Florida) -- Recent research shows that diabetes is an epidemic affecting an estimated 150 million people worldwide--and those numbers are expected to double in the next 15 years. Now a new research proven product called Emulin˙ from ATM Metabolics is being launched that is showing great promise reducing the damage of diabetes in recent trials. Emulin is an impressive therapy for the treatment of type 2 diabetes that can reduce the amount and rate of sugar that can be absorbed into the bloodstream and lessen the glycemic impact of foods. Furthermore, it appears to have the ability to reduce the background (fasting) level of glucose in the blood of type 2 diabetics, showing the potential to lessen the damage to tissue.
